Inclined Positioning and Infant Gastroesophageal Reflux (Infant GER)

April 27, 2022 updated by: Ian M. Paul, MD, Milton S. Hershey Medical Center

Inclined Positioning and Infant Gastroesophageal Reflux Indicators

The purpose of this voluntary research study is to evaluate the extent to which infants with Gastroesophageal Reflux (GER) exhibit oxygen desaturation (low oxygen levels in their blood) and bradycardia (slow heart rate) in supine (lying flat on back) and inclined positions.

Study Overview

Status

Completed

Detailed Description

Mothers will bring their infants to the Clinical Research Center where they will be escorted to a private room. Participants will proceed to feed their infant a typical liquid meal (i.e. breastmilk or formula). Within 15 minutes of completion of the feed, infants will be placed in the prototype infant reclining device at either 0, 10, 18, or 28 degrees of incline. Infants will spend 15 minutes at each level of incline in a randomly assigned order. During this time period that each infant is under observation the infant may be entertained/distracted/comforted with white noise, music or other forms of distraction as determined by the mother or study team. Mothers may touch/caress their infant or use a pacifier to soothe infant as needed so long as each 15 minute segment is completed. Following each 15 minute segment, a "washout" period will be used such that the next 15 minute segment will not begin for a minimum of 1 minute to a maximum of 5 minutes in duration before the next incline position is begun. This allows for a clean start and stop period for each 15 minute segment that is not impacted by either the prior position or the change to the new position. This also allows mothers or study staff to pick up and comfort the infant.

During each of the four 15 minute segments, infants will be monitored using the Masimo RAD-97 pulse oximeter with data continuously collected regarding oxygen saturation and heart rate in 2-second intervals. The oxygen saturation probe will preferably be attached to a big toe, but can be placed in alternative spots consistent with usual clinical care such that a consistent reading of heart rate and oxygen saturation are recorded. A study coordinator will complete a data collection form for each segment characterizing whether GER occurred (spit-up into mouth or outside of mouth), the number of GER episodes as well as a subjective assessment of degree crying/fussing, hiccups, back arching, and breathing difficulty. The coordinator will also have a timer to measure the duration of crying in each position. Infants will be video recorded as a backup method for symptom assessment and for qualitative assessments by the study sponsor.

Study Type

Observational

Enrollment (Actual)

35

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Pennsylvania
      • Hershey, Pennsylvania, United States, 17033
        • Penn State Milton S Hershey Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 month to 5 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Participants will be identified through providers in the Divisions of Academic General Pediatrics, Hospital Pediatrics, and Pediatric Gastroenterology. The Department of Family and Community Medicine may also refer participants to the study.

Description

Inclusion Criteria:

  • born at >= 34 weeks gestation
  • weight for age >= 10th percentile
  • No serious medical conditions
  • English-speaking parent capable of consenting
  • Diagnosis of GER from healthcare provider (not necessary for controls)
  • 4 or more visible spit-ups (mouth or nose) per day for at least 5 days OR 2 or more spit-ups out of the nose per day for at least 5 days OR I-GERQ score >=16 (not necessary for controls)
  • If applicable, parent willing to refrain from giving medication for GER for 12 hours prior to study participation

Exclusion Criteria:

  • Signs of a more serious or complex illness including weight loss, lethargy, fever, excessive irritability/pain, bulging fontanelle, seizures, macro/microcephaly, bilious vomiting, hematemesis, chronic diarrhea, rectal bleeding, suspicions of GI obstruction
  • History of a Brief Resolved Unexplained Event (BRUE)
  • Use of a Home Apnea Monitor prescribed by a healthcare provider

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Infants with GER
Infants (N=25) meeting inclusion/exclusion criteria
Controls without GER
Infants (N=10) meeting inclusion/exclusion criteria, but no GER

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of hypoxic episodes
Time Frame: 1 hour observation period
Evaluate the extent to which infants exhibit oxygen desaturation (oxygen saturation <94%) in each position
1 hour observation period
Number of bradycardia episodes
Time Frame: 1 hour observation period
Evaluate the extent to which infants exhibit bradycardia (heart rate <100 beats per minute) in each position
1 hour observation period
Number of observed regurgitations
Time Frame: 1 hour observation periods
Evaluate the extent to which infants exhibit clinical signs and symptoms of post-feed regurgitation in each position
1 hour observation periods

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time spent in hypoxic episodes
Time Frame: 1 hour observation period
Minutes spent in hypoxia in each position
1 hour observation period
Time spent in bradycardic episodes
Time Frame: 1 hour observation period
Minutes spent in bradycardia in each position
1 hour observation period
Time spent fussing or crying
Time Frame: 1 hour observation period
Minutes spent fussing or crying in each position
1 hour observation period
Observed cyanosis episodes
Time Frame: 1 hour observation period
Number of episodes of observed cyanosis (turning blue) in each position
1 hour observation period
Subjective assessment of crying, hiccups, back arching, and respiratory distress
Time Frame: 1 hour observation period
Yes/no answer in each position
1 hour observation period
Subjective maternal perception of infant comfort in each position
Time Frame: 1 hour observation period
very comfortable, comfortable, neither comfortable nor uncomfortable, uncomfortable, very uncomfortable
1 hour observation period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Ian M Paul, MD, Penn State College of Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 15, 2021

Primary Completion (Actual)

January 25, 2022

Study Completion (Actual)

January 25, 2022

Study Registration Dates

First Submitted

September 1, 2020

First Submitted That Met QC Criteria

September 4, 2020

First Posted (Actual)

September 9, 2020

Study Record Updates

Last Update Posted (Actual)

April 29, 2022

Last Update Submitted That Met QC Criteria

April 27, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastroesophageal Reflux

3
Subscribe